Cell Therapy News Volume 27.03 | Mar 2 2026

    0
    34






    2026-03-02 | CTN 27.03


    Cell Therapy News by STEMCELL Technologies
    Vol. 27.03 – 02 March, 2026
    TOP STORY

    TRIM13 In Situ Engineering Boosts Anti-Inflammatory Capacity of CAR-Ms for Liver Fibrosis Therapy

    Scientists reported tripartite motif containing 13 (TRIM13) engineered CAR-macrophages (CAR-Ms) for effectively manipulating the anti-inflammatory phenotype of CAR-Ms, augmenting their anti-fibrosis efficacy.
    [Nature]

    Full Article
    Explore this validated protocol for the gene-editing of Human CD34+ Hematopoietic Stem and Progenitor Cells using the ArciTectâ„¢ CRISPR-Cas9 System.
    PUBLICATIONSListed by the impact factor of the journal

    OR7A10 GPCR Engineering Boosts CAR-NK Therapy against Solid Tumours

    Engineering CAR-NK cells with OR7A10 cDNA enhanced their proliferation, activation, degranulation, cytokine production, death ligand expression, chemokine receptor expression, cytotoxicity, persistence, metabolic fitness, and tumor microenvironment resistance.
    [Nature]

    Abstract

    MyD88-Mediated Chimaeric Antigen Receptor Macrophages Suppress Brain Metastasis Using Target-Specific Phagocytosis

    Given the unique abilities of macrophages to cross the blood–brain barrier and exert their phagocytic function on tumor cells, researchers genetically engineered macrophages that expressed a CAR targeting mesothelin.
    [Nature Biomedical Engineering]

    Abstract

    Antigen-Boosted CD4 CAR-T Cells Fail to Expand or Control Viremia in Multiple Nonhuman Primate Models of HIV

    Researchers tested a broad array of strategies to enhance CD4CAR-T cell efficacy, including CRISPR-Cas9-mediated gene editing of immune checkpoint and HIV-associated genes, single and pooled competitive infusions of engineered CAR-T cells, and exogenous antigen boosting.
    [Blood]

    Abstract

    Pluripotent Stem Cell-Derived CAR-NK Progenitor Therapy Targets Minimal Residual Disease and Prevents Relapse in Leukemia Models

    Scientists developed a PSC-derived induced natural killer lineage-committed progenitor cell therapy (iNKP) in leukemia models. They generated abundant iNKP cells via an organoid culture system.
    [Cell Stem Cell]

    Abstract | Graphical Abstract

    KRASG12V/HLA-a*02:01-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity against Solid Tumors

    Investigators developed CAR T cells targeting KRASG12V/HLA-A*02:01 using phage antibody display to identify high-affinity single-chain variable fragments.
    [Science Advances]

    Full Article

    Effective Allogeneic Natural Killer Cell Therapy for Pancreatic Adenocarcinoma Avails Conserved Activating Receptors and Evades HLA I-Driven Inhibition

    In natural killer (NK)-competent humanized mice, adoptively transferred, unselected, unmodified NK cells slowed tumor growth in a dose-dependent manner, but NK cells selected to avoid HLA I-driven inhibition were the most competent effectors for PDAC control.
    [Journal for Immunotherapy of Cancer]

    Full Article
    This webinar provides insights and techniques for efficient leukopak sample processing and streamlined cell isolation.
    REVIEWS

    Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity

    The authors review the clinical progress of engineered cellular immunotherapies for autoimmunity, focusing on how antigenic target, engineered cell type, CAR design, and treatment regimens affect the therapeutic efficacy and safety of these treatments.
    [Nature Biotechnology]

    Abstract

    Cardiotoxicity of T Cell Immunotherapies

    Scientists summarize the mechanisms, epidemiology and management of T cell therapy-associated cytokine release syndrome and subsequent cardiotoxicity.
    [Nature Reviews Cardiology]

    Abstract

    CAR T Cells and T Cell Engagers for Autoimmunity-Lessons from Hematology

    Investigators explore key insights gained from hematologic applications of CAR T cells and T cell engagers, and discuss how these lessons can guide the clinical use of these therapies in autoimmune diseases.
    [Bone Marrow Transplantation]

    Abstract
    INDUSTRY AND POLICY NEWS

    A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster

    A2 Biotherapeutics, Inc. announced the first patient dosed with A2B543, an autologous CAR T cell therapy, initiating the second arm of the Phase I/II EVEREST-2 study.
    [A2 Biotherapeutics, Inc.]

    Press Release

    Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors

    Cellares and the University of Wisconsin School of Medicine and Public Health announced an expansion of their partnership to support clinical production and regulatory advancement of the university’s CRISPR-edited GD2 CAR-T investigational therapy for pediatric and adult solid tumors.
    [Cellares (Business Wire, Inc.)]

    Press Release

    B.C. Research ‘Opens the Door’ to More Effective Cancer Therapies

    Researchers at the University of British Columbia and B.C. Children’s Hospital Research Institute have recently discovered how to use stem cells to create the immune cells needed for effective cell therapy.
    [Canadian Affairs]

    Press Release
    FEATURED EVENT

    BSGCT Annual Conference 2026

    April 15-17, 2026
    Newcastle upon Tyne, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Scientist – Pediatric Immune-Oncology

    St Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Postdoc Program – Biomedical Research

    Research Center for Molecular Medicine – Vienna, Austria

    Postdoctoral Research Associate – Oncology

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Tenure-Track Professor/Associate Professor/Assistant Professor – Biomedical Sciences

    The University of Hong Kong – Hong Kong

    Group Leader – Genome Editing/Cellular immunotherapy

    Vilnius University Life Sciences Center – Vilnius, Lithuania

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2